Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Genocea Biosciences Inc (NASDAQ:GNCA)

5.26
Delayed Data
As of Jun 27
 -0.14 / -2.59%
Today’s Change
3.28
Today|||52-Week Range
7.29
+27.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$153.9M

Company Description

Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company uses its proprietary ATLAS™ antigen identification platform to build a pipeline of immunotherapies that currently includes GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine, for which an Investigational New Drug application filing is expected by the end of 2017. Genocea Biosciences was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Contact Information

Genocea Biosciences, Inc.
Cambridge Discovery Park
Cambridge Massachusetts 02140
P:(617) 876-8191
Investor Relations:
(617) 715-7795

Employees

Shareholders

Mutual fund holders32.43%
Individual stakeholders30.67%
Other institutional17.04%

Top Executives

Chip ClarkPresident, Chief Executive Officer & Director
Jonathan Michael PooleChief Financial Officer & Head-Investor Relations
Jessica Baker FlechtnerChief Scientific Officer
Seth V. HetheringtonChief Medical Officer
Eric S. HoffmanChief Business Officer